Catalyst for Expansion: Oncology and Theranostics Drivers In 2026, oncology remains the dominant application segment, accounting for over 65% of the France Radiopharmaceuticals Market share. The France Radiopharmaceuticals Market growth is currently supercharged by the success of PSMA-targeted therapies for prostate cancer. Clinical results from French university hospitals (CHUs) have shown that radioligand therapy significantly improves progression-free survival, leading to a surge in demand for Ga-68 PSMA (diagnostic) and Lu-177 PSMA (therapeutic) pairings. https://www.marketresearchfuture.com/reports/france-radiopharmaceuticals-market-43853 Another major driver is the "Green Nuclear" movement. France is pioneering the use of specialized cyclotrons that can produce medical isotopes with significantly lower carbon footprints and less long-term waste than traditional nuclear reactors. This "Ecological Transition" in nuclear medicine is highly supported by French regulatory bodies (ASN), which are streamlining the approval process for "short-lived" isotopes that decay quickly, thereby increasing patient throughput in imaging centers and reducing the environmental impact of hospital discharges. FAQ: Question: Why is prostate cancer therapy so important for this market? Answer: Prostate cancer is highly prevalent in France; new radiopharmaceuticals offer a highly effective "search and destroy" mechanism for metastatic cases. Question: How does a "Cyclotron" differ from a reactor in this context? Answer: Cyclotrons are smaller, particle-accelerator-based units that can be placed closer to hospitals to produce isotopes on-demand.